XML 168 R116.htm IDEA: XBRL DOCUMENT
v3.19.1

Financial Assets at Amortized Cost-Securities - Summary of Reconciliation of Expected Loss to Financial Assets at Amortized Cost - Securities, Segregated by Stages (Detail) - BRL (R$) R$ in Millions | 12 Months Ended
--- | ---
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016
Stage 1 [Member] |  |  |
Disclosure of maturity analysis for derivative financial assets designated at fair value through profit or loss [Line Items] |  |  |
Expected loss | R$ (76) | R$ (82) | R$ (199)
Gains / (Losses) | (129) | (24) | 31
Purchases | (28) | (44) | (34)
Settlements | 14 | 48 | 60
Transfer to Stage 2 |  |  | 12
Transfer to Stage 3 |  | 26 | 48
Cure from Stage 2 | (4) |  |
Cure from Stage 3 | 0 | 0 | 0
Expected loss | (223) | (76) | (82)
Stage 1 [Member] | Corporate securities [member] |  |  |
Disclosure of maturity analysis for derivative financial assets designated at fair value through profit or loss [Line Items] |  |  |
Expected loss | (73) | (79) | (199)
Gains / (Losses) | (130) | (24) | 31
Purchases | (26) | (44) | (31)
Settlements | 14 | 48 | 60
Transfer to Stage 2 |  |  | 12
Transfer to Stage 3 |  | 26 | 48
Cure from Stage 2 | (4) |  |
Cure from Stage 3 | 0 | 0 | 0
Expected loss | (219) | (73) | (79)
Stage 1 [Member] | Corporate securities [member] | Rural product note [Member] |  |  |
Disclosure of maturity analysis for derivative financial assets designated at fair value through profit or loss [Line Items] |  |  |
Expected loss | (9) | (4) | (2)
Gains / (Losses) | 5 | (2) | (1)
Purchases | (7) | (7) | (2)
Settlements | 4 | 4 | 1
Cure from Stage 3 | 0 | 0 | 0
Expected loss | (7) | (9) | (4)
Stage 1 [Member] | Corporate securities [member] | Securitized real estate loans [Member] |  |  |
Disclosure of maturity analysis for derivative financial assets designated at fair value through profit or loss [Line Items] |  |  |
Expected loss | (9) | (17) | (54)
Gains / (Losses) | 5 | (3) | 1
Settlements | 2 |  | 1
Transfer to Stage 2 |  |  | 2
Transfer to Stage 3 |  | 11 | 33
Cure from Stage 3 | 0 | 0 | 0
Expected loss | (2) | (9) | (17)
Stage 1 [Member] | Corporate securities [member] | Debentures [member] |  |  |
Disclosure of maturity analysis for derivative financial assets designated at fair value through profit or loss [Line Items] |  |  |
Expected loss | (52) | (50) | (109)
Gains / (Losses) | (140) | (20) | 27
Purchases | (18) | (35) | (25)
Settlements | 8 | 39 | 35
Transfer to Stage 2 |  |  | 10
Transfer to Stage 3 |  | 14 | 12
Cure from Stage 2 | (4) |  |
Cure from Stage 3 | 0 | 0 | 0
Expected loss | (206) | (52) | (50)
Stage 1 [Member] | Corporate securities [member] | Eurobonds and others [member] |  |  |
Disclosure of maturity analysis for derivative financial assets designated at fair value through profit or loss [Line Items] |  |  |
Expected loss | (2) | (5) | (32)
Gains / (Losses) |  | 1 | 4
Purchases |  | (1) | (2)
Settlements |  | 3 | 22
Transfer to Stage 3 |  |  | 3
Cure from Stage 3 | 0 | 0 | 0
Expected loss | (2) | (2) | (5)
Stage 1 [Member] | Corporate securities [member] | Promissory notes [Member] |  |  |
Disclosure of maturity analysis for derivative financial assets designated at fair value through profit or loss [Line Items] |  |  |
Expected loss | (1) | (1) | (2)
Purchases | (1) | (1) |
Settlements |  | 1 | 1
Cure from Stage 3 | 0 | 0 | 0
Expected loss | (2) | (1) | (1)
Stage 1 [Member] | Corporate securities [member] | Other [member] |  |  |
Disclosure of maturity analysis for derivative financial assets designated at fair value through profit or loss [Line Items] |  |  |
Expected loss |  | (2) |
Purchases |  |  | (2)
Settlements |  | 1 |
Transfer to Stage 3 |  | 1 |
Cure from Stage 3 |  | 0 | 0
Expected loss |  |  | (2)
Stage 1 [Member] | Colombia [member] | Government securities - abroad [member] |  |  |
Disclosure of maturity analysis for derivative financial assets designated at fair value through profit or loss [Line Items] |  |  |
Expected loss | (3) | (3) |
Gains / (Losses) | 1 |  |
Purchases | (2) |  | (3)
Cure from Stage 3 | 0 | 0 | 0
Expected loss | (4) | (3) | (3)
Stage 2 [Member] |  |  |
Disclosure of maturity analysis for derivative financial assets designated at fair value through profit or loss [Line Items] |  |  |
Expected loss | (368) | (438) | (385)
Gains / (Losses) | (12) | (73) | 21
Purchases | (561) | (281) | (131)
Settlements | 6 | 314 | 161
Transfer to Stage 1 | 51 |  |
Transfer to Stage 3 | 74 | 176 | 68
Cure from Stage 1 | (14) | (66) | (172)
Cure from Stage 3 | 0 | 0 | 0
Expected loss | (824) | (368) | (438)
Stage 2 [Member] | Corporate securities [member] |  |  |
Disclosure of maturity analysis for derivative financial assets designated at fair value through profit or loss [Line Items] |  |  |
Expected loss | (303) | (366) | (307)
Gains / (Losses) | (18) | (80) | 15
Purchases | (561) | (281) | (131)
Settlements | 6 | 314 | 161
Transfer to Stage 1 | 51 |  |
Transfer to Stage 3 | 74 | 176 | 68
Cure from Stage 1 | (14) | (66) | (172)
Cure from Stage 3 | 0 | 0 | 0
Expected loss | (765) | (303) | (366)
Stage 2 [Member] | Corporate securities [member] | Rural product note [Member] |  |  |
Disclosure of maturity analysis for derivative financial assets designated at fair value through profit or loss [Line Items] |  |  |
Expected loss |  | (30) | (26)
Gains / (Losses) | 11 | (3) | 11
Purchases | (22) |  | (17)
Settlements |  | 33 | 2
Transfer to Stage 3 | 11 |  |
Cure from Stage 3 | 0 | 0 | 0
Expected loss |  |  | (30)
Stage 2 [Member] | Corporate securities [member] | Securitized real estate loans [Member] |  |  |
Disclosure of maturity analysis for derivative financial assets designated at fair value through profit or loss [Line Items] |  |  |
Expected loss | (5) | (50) | (6)
Gains / (Losses) |  | 2 |
Transfer to Stage 3 | 6 | 43 | 6
Cure from Stage 1 | (1) |  | (50)
Cure from Stage 3 | 0 | 0 | 0
Expected loss |  | (5) | (50)
Stage 2 [Member] | Corporate securities [member] | Debentures [member] |  |  |
Disclosure of maturity analysis for derivative financial assets designated at fair value through profit or loss [Line Items] |  |  |
Expected loss | (284) | (286) | (223)
Gains / (Losses) | (22) | (79) | 4
Purchases | (539) | (267) | (114)
Settlements | 1 | 281 | 107
Transfer to Stage 1 | 51 |  |
Transfer to Stage 3 | 36 | 133 | 62
Cure from Stage 1 | (8) | (66) | (122)
Cure from Stage 3 | 0 | 0 | 0
Expected loss | (765) | (284) | (286)
Stage 2 [Member] | Corporate securities [member] | Eurobonds and others [member] |  |  |
Disclosure of maturity analysis for derivative financial assets designated at fair value through profit or loss [Line Items] |  |  |
Expected loss |  |  | (13)
Settlements | 5 |  | 13
Cure from Stage 1 | (5) |  |
Cure from Stage 3 | 0 |  | 0
Stage 2 [Member] | Corporate securities [member] | Other [member] |  |  |
Disclosure of maturity analysis for derivative financial assets designated at fair value through profit or loss [Line Items] |  |  |
Expected loss | (14) |  | (39)
Gains / (Losses) | (7) |  |
Purchases |  | (14) |
Settlements |  |  | 39
Transfer to Stage 3 | 21 |  |
Cure from Stage 3 | 0 | 0 | 0
Expected loss |  | (14) |
Stage 2 [Member] | Brazil [Member] | Government securities - abroad [member] |  |  |
Disclosure of maturity analysis for derivative financial assets designated at fair value through profit or loss [Line Items] |  |  |
Expected loss | (65) | (72) | (78)
Gains / (Losses) | 6 | 7 | 6
Cure from Stage 3 | 0 | 0 | 0
Expected loss | (59) | (65) | (72)
Stage 3 [Member] |  |  |
Disclosure of maturity analysis for derivative financial assets designated at fair value through profit or loss [Line Items] |  |  |
Expected loss | (4,738) | (3,298) | (425)
Gains / (Losses) | 784 | (528) | (186)
Purchases | (594) | (1,276) | (720)
Settlements | 2,065 | 1,221 | 176
Cure from Stage 1 |  | (115) | (1,699)
Cure from Stage 2 | (116) | (742) | (444)
Expected loss | (2,599) | (4,738) | (3,298)
Stage 3 [Member] | Corporate securities [member] |  |  |
Disclosure of maturity analysis for derivative financial assets designated at fair value through profit or loss [Line Items] |  |  |
Expected loss | (4,738) | (3,298) | (425)
Gains / (Losses) | 784 | (528) | (186)
Purchases | (594) | (1,276) | (720)
Settlements | 2,065 | 1,221 | 176
Cure from Stage 1 |  | (115) | (1,699)
Cure from Stage 2 | (116) | (742) | (444)
Expected loss | (2,599) | (4,738) | (3,298)
Stage 3 [Member] | Corporate securities [member] | Rural product note [Member] |  |  |
Disclosure of maturity analysis for derivative financial assets designated at fair value through profit or loss [Line Items] |  |  |
Expected loss | (148) | (56) |
Gains / (Losses) | (106) | (37) | (56)
Purchases | (36) | (55) |
Settlements | 127 |  |
Cure from Stage 2 | (10) |  |
Expected loss | (173) | (148) | (56)
Stage 3 [Member] | Corporate securities [member] | Securitized real estate loans [Member] |  |  |
Disclosure of maturity analysis for derivative financial assets designated at fair value through profit or loss [Line Items] |  |  |
Expected loss | (2,046) | (1,650) | (10)
Gains / (Losses) | 463 | (200) | (1)
Purchases |  |  | (95)
Settlements | 1,244 | 125 | 10
Cure from Stage 1 |  | (115) | (1,321)
Cure from Stage 2 | (22) | (206) | (233)
Expected loss | (361) | (2,046) | (1,650)
Stage 3 [Member] | Corporate securities [member] | Debentures [member] |  |  |
Disclosure of maturity analysis for derivative financial assets designated at fair value through profit or loss [Line Items] |  |  |
Expected loss | (2,522) | (1,469) | (285)
Gains / (Losses) | 432 | (294) | (149)
Purchases | (558) | (1,199) | (623)
Settlements | 678 | 976 | 61
Cure from Stage 1 |  |  | (262)
Cure from Stage 2 | (67) | (536) | (211)
Expected loss | (2,037) | (2,522) | (1,469)
Stage 3 [Member] | Corporate securities [member] | Eurobonds and others [member] |  |  |
Disclosure of maturity analysis for derivative financial assets designated at fair value through profit or loss [Line Items] |  |  |
Expected loss |  | (101) | (52)
Gains / (Losses) |  | 3 | 20
Purchases |  |  | (2)
Settlements |  | 98 | 27
Cure from Stage 1 |  |  | (94)
Expected loss |  |  | (101)
Stage 3 [Member] | Corporate securities [member] | Promissory notes [Member] |  |  |
Disclosure of maturity analysis for derivative financial assets designated at fair value through profit or loss [Line Items] |  |  |
Expected loss | (22) | (22) | (78)
Gains / (Losses) | (5) |  |
Purchases |  | (22) |
Settlements | 16 | 22 | 78
Cure from Stage 1 |  |  | (22)
Expected loss | (11) | R$ (22) | R$ (22)
Stage 3 [Member] | Corporate securities [member] | Other [member] |  |  |
Disclosure of maturity analysis for derivative financial assets designated at fair value through profit or loss [Line Items] |  |  |
Cure from Stage 2 | (17) |  |
Expected loss | R$ (17) |  |

X
- Definition The gains (losses) on financial assets measured at amortised cost. [Refer: Financial assets at amortised cost] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Note Effective 2018-01-01 -Name IFRS -Number 7 -IssueDate 2017-01-01 -Paragraph 20 -Subparagraph a -Clause vi -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&num=7&date=2017-03-01&anchor=para_20_a_vi&doctype=Standard -URIDate 2017-03-09 + Details
Name: | ifrs-full_GainsLossesOnFinancialAssetsAtAmortisedCost
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Cure from stage one of financial assets at amortized cost. + References No definition available. + Details
Name: | itub_CureFromStageOneOfFinancialAssetsAtAmortizedCost
Namespace Prefix: | itub_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Cure from stage three of financial assets at amortized cost. + References No definition available. + Details
Name: | itub_CureFromStageThreeOfFinancialAssetsAtAmortizedCost
Namespace Prefix: | itub_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Cure from stage two of financial assets at amortized cost. + References No definition available. + Details
Name: | itub_CureFromStageTwoOfFinancialAssetsAtAmortizedCost
Namespace Prefix: | itub_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Disclosure of maturity analysis for derivative financial assets designated at fair value through profit or loss. + References No definition available. + Details
Name: | itub_DisclosureOfMaturityAnalysisForDerivativeFinancialAssetsDesignatedAtFairValueThroughProfitOrLossLineItems
Namespace Prefix: | itub_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Financial assets expected loss. + References No definition available. + Details
Name: | itub_FinancialAssetsExpectedLoss
Namespace Prefix: | itub_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Purchases of financial investments. + References No definition available. + Details
Name: | itub_PurchasesOfFinancialInvestments
Namespace Prefix: | itub_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Settlement Of Financial Assets At Amortised Cost + References No definition available. + Details
Name: | itub_SettlementOfFinancialAssetsAtAmortisedCost
Namespace Prefix: | itub_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Transfer to stage one of financial assets at amortized cost. + References No definition available. + Details
Name: | itub_TransferToStageOneOfFinancialAssetsAtAmortizedCost
Namespace Prefix: | itub_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Transfer to stage Three of financial assets at amortized cost + References No definition available. + Details
Name: | itub_TransferToStageThreeOfFinancialAssetsAtAmortizedCost
Namespace Prefix: | itub_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Transfer to stage Two of financial assets at amortized cost + References No definition available. + Details
Name: | itub_TransferToStageTwoOfFinancialAssetsAtAmortizedCost
Namespace Prefix: | itub_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | ifrs-full_ImpairmentOfFinancialAssetsAxis=itub_StageOneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfFinancialAssetsAxis=itub_CorporateSecuritiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfFinancialInstrumentsAxis=itub_RuralProductNoteMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfFinancialInstrumentsAxis=itub_SecuritizedRealEstateLoansMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfFinancialInstrumentsAxis=itub_DebenturesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfFinancialInstrumentsAxis=itub_EurobondsAndOthersMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfFinancialInstrumentsAxis=itub_PromissoryNotesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfFinancialInstrumentsAxis=itub_OtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | itub_CountryNameAxis=country_CO
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfFinancialAssetsAxis=itub_GovernmentSecuritiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ImpairmentOfFinancialAssetsAxis=itub_StageTwoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | itub_CountryNameAxis=country_BR
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ImpairmentOfFinancialAssetsAxis=itub_StageThreeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |